A T van der Ploeg
Overview
Explore the profile of A T van der Ploeg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Harlaar L, Ciet P, van der Ploeg A, Brusse E, van der Beek N, Wielopolski P, et al.
Neuromuscul Disord
. 2018 Feb;
28(3):246-256.
PMID: 29398294
Respiratory muscle weakness frequently occurs in patients with neuromuscular disease. Measuring respiratory function with standard pulmonary function tests provides information about the contribution of all respiratory muscles, the lungs and...
12.
van der Ploeg A, Kruijshaar M, Toscano A, Laforet P, Angelini C, Lachmann R, et al.
Eur J Neurol
. 2017 May;
24(6):768-e31.
PMID: 28477382
Background And Purpose: Pompe disease is a rare inheritable muscle disorder for which enzyme replacement therapy (ERT) has been available since 2006. Uniform criteria for starting and stopping ERT in...
13.
Gungor D, Kruijshaar M, Plug I, Rizopoulos D, Kanters T, Wens S, et al.
J Neuromuscul Dis
. 2016 Nov;
2(s1):S63.
PMID: 27858652
No abstract available.
14.
van der Meijden J, Gungor D, Kruijshaar M, Muir A, Broekgaarden H, van der Ploeg A
J Neuromuscul Dis
. 2016 Nov;
2(s1):S35.
PMID: 27858630
No abstract available.
15.
van Capelle C, van der Meijden J, van den Hout J, Jaeken J, Baethmann M, Voit T, et al.
Orphanet J Rare Dis
. 2016 May;
11(1):65.
PMID: 27189384
Background: As little information is available on children with non-classic presentations of Pompe disease, we wished to gain knowledge of specific clinical characteristics and genotypes. We included all patients younger...
16.
Rutten M, Ciet P, Biggelaar R, Oussoren E, Langendonk J, van der Ploeg A, et al.
Orphanet J Rare Dis
. 2016 Apr;
11:50.
PMID: 27112191
Background: Mucopolysaccharidosis type II (MPSII) patients frequently suffer from dyspnoea caused by restrictive airway disease due to skeletal abnormalities as well as glycosaminoglycans (GAG) accumulation at different levels of the...
17.
Meijer O, Welling L, Valstar M, Hoefsloot L, Bruggenwirth H, van der Ploeg A, et al.
J Inherit Metab Dis
. 2016 Feb;
39(3):437-445.
PMID: 26907177
Background: Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare genetic disorder in which the deficiency of the lysosomal enzyme N-acetyl-α-glucosaminidase (NAGLU) results in the accumulation of heparan sulfate (HS), leading...
18.
van Gelder C, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser A, et al.
J Inherit Metab Dis
. 2016 Jan;
39(3):383-390.
PMID: 26768149
Background: Though enzyme-replacement therapy (ERT) with alglucosidase alfa has significantly improved the prospects for patients with classic infantile Pompe disease, some 50 % of treated infants do not survive ventilator-free...
19.
Kanters T, Redekop W, Kruijshaar M, van der Ploeg A, Rutten-van Molken M, Hakkaart L
Qual Life Res
. 2014 Oct;
24(4):837-44.
PMID: 25342117
Purpose: Comparative studies between Euroqol-5D (EQ-5D) and ShortForm 6D (SF-6D) utilities have been performed for a number of diseases, but not yet for orphan diseases. Pompe disease is an orphan...
20.
van der Meijden J, Gungor D, Kruijshaar M, Muir A, Broekgaarden H, van der Ploeg A
J Inherit Metab Dis
. 2014 Aug;
38(3):495-503.
PMID: 25112389
Pompe disease is a rare, progressive lysosomal storage disorder for which enzyme therapy (ERT) became available in 2006. Four years earlier, the IPA/Erasmus MC survey, an international longitudinal prospective survey,...